SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with knife is driving intense community engagement through its multichain presence and deflationary burn mechanism, with supporters actively building a cult-like following. Investors are heavily focused on the project's long-term potential, frequently encouraging others to increase their positions while highlighting the meme's unique brand identity.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is trending as investors react to a significant executive order accelerating research pathways for psychedelic-based therapies, which has bolstered confidence in the sector's regulatory outlook. The community is actively discussing the potential for institutional re-rating, strong cash reserves, and upcoming Phase 3 trial data, with many debating the company's status as a top buyout candidate.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is drawing attention as investors highlight its fundamental strength and consistent revenue generation compared to other DeFi protocols. The community remains focused on long-term accumulation, closely monitoring technical support levels and broader market volatility as traders debate the project's potential for future growth.

Highstreet

Highstreet is seeing intense community debate and speculative trading as users analyze its potential for a short squeeze following a significant pullback from previous highs. Discussions are heavily polarized, with many traders debating the risk of further declines against the potential for a rapid technical reversal based on low supply and oversold indicators.

PolySwarm

PolySwarm is capturing investor attention as the community anticipates a long-awaited breakout, driven by its cybersecurity utility and low market cap. Discussion is currently dominated by bullish sentiment regarding the token's potential for explosive gains, whale accumulation patterns, and hopes for upcoming catalysts that could trigger a significant price reversal.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is experiencing significant volatility and heightened investor interest as the market reacts to a major rebrand and leadership changes, while simultaneously tracking key clinical catalysts including Phase 2 readouts for its anxiety pipeline and Phase 3 progress for its lead depression program. Community discussions are deeply polarized, with some investors focusing on the company's strong patent portfolio and potential for a sector-wide regulatory re-rating, while others remain skeptical due to historical dilution, poor stock performance, and the company's rebranding efforts.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is attracting significant community attention as users debate its long-term potential as a decentralized cloud infrastructure alternative to Big Tech. While some investors remain skeptical due to past price performance and dilution concerns, proponents are actively promoting its technical milestones like the Caffeine.ai integration and the launch of sovereign subnets as catalysts for future mainstream adoption.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as market sentiment surges following news of the company's progress toward late-stage clinical trials for PTSD and an accelerated timeline for treatment-resistant depression commercialization. The community is actively discussing the stock's potential for FDA approval and future M&A activity, with retail sentiment buoyed by the prospect of policy tailwinds in the psychedelic-assisted therapy sector.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems is trending due to anticipation surrounding the upcoming CHOPIN trial data, expected in mid-October, which investors hope will validate the platform's clinical value and potentially expand the Hepzato Kit's use as a frontline treatment. While recent revenue guidance and management's explanation of seasonal slowdowns caused significant volatility, the community remains divided, with bulls pointing to growing center activations, strong gross margins, and long-term pipeline potential in additional cancer indications as reasons to accumulate at lower price levels.

Shido

Shido is seeing significant community momentum as the project advances its Shido Network with the recent Nova EVM stage net deployment and the launch of the Shido DEX V4 interface upgrade. Investors are actively discussing the ecosystem's expanding toolsetincluding the Bubble Protocol integration and AI-enhanced chain analyticswhile maintaining a long-term, high-conviction outlook on the project's infrastructure-focused growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CAAS I managed several good size fills at 4.16-4.18.  Even with this as one of my larger position I would double it if we got to 4.   Will repeat again - selling at  33% of tangible book value, 0.2 times P/S and 4 times earnings, growing at 20%+ and international expansion.

StockTwits Web

China Automotive Systems Inc

 I managed several good size fills at 4.16-4.18.  Even with this as one of my larger position I would double it if we got to 4.   Will repeat again - selling at  33% of tangible book value, 0.2 times P/S and 4 times earnings, growing at 20%+ and international expansion.

Autohome

Baozun

Yiren Digital Ltd.

Lamb Weston Holdings Inc

GreenTree Hospitality

Qifu Technology Inc - ADR

Lufax Holding Ltd - ADR

Alvotech

JohnTill

@JohnTill Saw this war coming from a mile away, even tried to bet on it on polymarket (but was banned in my country) and I didn&#39;t sell EM equities lol. Sometimes I wonder if Im an idiot.

 Saw this war coming from a mile away, even tried to bet on it on polymarket (but was banned in my country) and I didn't sell EM equities lol. Sometimes I wonder if Im an idiot.

Inmode Ltd

Radcom

JD.com Inc - ADR

111 Inc - ADR

@i_jw The war was obvious but not the market reaction.  I put on a massive hedge yesterday since I guess we would have a COVID type situation.  Initially people just kissed COVID right off and markets hit new highs - until they didn&#39;t. 
 
I am my by far my toughest critic and at least a few times a day wonder if I also am an idiot.  I rarely celebrate the wins but revisit mistakes often.  I find the toughest thing in these types of situations is loading way too soon and not having ammo when things get really, really crazy.  2002, 2008 and 2020 were all life lessons for me on that one and ran out of ammo before the bottoms in all three cases.  However, I also find it so hard to have the patience to wait when you see numbers like CAAS and not fully load.  Why do we trade again and worst job ever.

Mr. Sandman

 The war was obvious but not the market reaction.  I put on a massive hedge yesterday since I guess we would have a COVID type situation.  Initially people just kissed COVID right off and markets hit new highs - until they didn't. 
 
I am my by far my toughest critic and at least a few times a day wonder if I also am an idiot.  I rarely celebrate the wins but revisit mistakes often.  I find the toughest thing in these types of situations is loading way too soon and not having ammo when things get really, really crazy.  2002, 2008 and 2020 were all life lessons for me on that one and ran out of ammo before the bottoms in all three cases.  However, I also find it so hard to have the patience to wait when you see numbers like CAAS and not fully load.  Why do we trade again and worst job ever.

@JohnTill Yeah seems to me this war will be background noise within 1-2 weeks. Bought more GRVY and ATHM

 Yeah seems to me this war will be background noise within 1-2 weeks. Bought more GRVY and ATHM

@JohnTill They had a P/E around 3.2 if you annualize Q3 right? More or less. In addition, they have this &quot;2030 plan&quot; of tripple revenue and of course increased margin as they scale. If they deliver, this can be easily a 10x. Funny it never surprises upwards though.  
Where do you have a larger position, here or GHG? I feel like moving GHG position, at least partially to this one, seems safer, surfing the EV wave in an agnostic way.

 They had a P/E around 3.2 if you annualize Q3 right? More or less. In addition, they have this "2030 plan" of tripple revenue and of course increased margin as they scale. If they deliver, this can be easily a 10x. Funny it never surprises upwards though.  
Where do you have a larger position, here or GHG? I feel like moving GHG position, at least partially to this one, seems safer, surfing the EV wave in an agnostic way.

X Financial

Jiayin Group Inc.

FinVolution Group - ADR

Olema Pharmaceuticals Inc

BriaCell Therapeutics Corp

Yuanbao Inc.

achilles

@indiefunda I was being generous by saying the PE was under 4.  All the numbers on CAAS from cash, to growth, to earnings are stunning and good point on the 2030 plan.  I actually have the exact same size on CAAS as GHG and both very healthy positions.  The only difference is I am underwater in a big way on GHG (avg. ~1.69) but close to breakeven on CAAS at current prices.

 I was being generous by saying the PE was under 4.  All the numbers on CAAS from cash, to growth, to earnings are stunning and good point on the 2030 plan.  I actually have the exact same size on CAAS as GHG and both very healthy positions.  The only difference is I am underwater in a big way on GHG (avg. ~1.69) but close to breakeven on CAAS at current prices.